8-K: Centessa Pharmaceuticals Reports Positive Q1 2025 Financial Results and Advances Orexin Agonist Pipeline

Centessa Pharmaceuticals announced its Q1 2025 financial results, highlighting progress in its orexin receptor 2 (OX2R) agonist pipeline, including the ORX750 Phase 2a CRYSTAL-1 study.

Summary

• Centessa Pharmaceuticals reported its financial results and business highlights for the first quarter ended March 31, 2025.
• The company is advancing its orexin receptor 2 (OX2R) agonist franchise, with key data readouts expected this year.
• The ORX750 Phase 2a CRYSTAL-1 study for narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH) is on track, with data expected across all three indications this year.
• ORX142 is on track to initiate first-in-human studies for neurological and neurodegenerative disorders, with clinical data in acutely sleep-deprived healthy volunteers planned for this year.
• ORX489 is advancing in IND-enabling studies for neuropsychiatric disorders.
• Cash, cash equivalents, and investments totaled $424.9 million as of March 31, 2025, expected to fund operations into mid-2027.
• Research & Development (R&D) expenses were $33.4 million for the first quarter ended March 31, 2025, compared to $22.7 million for the first quarter ended March 31, 2024.
• General & Administrative (G&A) expenses were $12.3 million for the first quarter ended March 31, 2025, compared to $13.4 million for the first quarter ended March 31, 2024.
• Net loss was $26.1 million for the first quarter ended March 31, 2025, compared to $38.0 million for the first quarter ended March 31, 2024.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the progress in the pipeline, strong cash position, and decrease in net loss. However, the company is still operating at a loss and faces risks associated with drug development.

Positives

• The company has a strong cash position of $424.9 million, expected to fund operations into mid-2027.
• Net loss decreased from $38.0 million in Q1 2024 to $26.1 million in Q1 2025.
• The company is making significant progress in its OX2R agonist pipeline, with multiple data readouts expected this year.
• ORX750 shows potential as a best-in-class OX2R agonist for the treatment of NT1, NT2, and IH, with first-in-class potential in NT2 and IH.
• ORX142 is on track to initiate first-in-human studies for neurological and neurodegenerative disorders.

Negatives

• The company reported a net loss of $26.1 million for the first quarter ended March 31, 2025.
• Research and development expenses increased from $22.7 million in Q1 2024 to $33.4 million in Q1 2025.

Risks

• The company's success depends on the successful development and commercialization of its product candidates.
• Clinical trials may not be successful, and regulatory approvals may not be obtained.
• The company faces competition from other pharmaceutical companies.
• Economic risks to the United States and United Kingdom banking systems could impact the company.
• Geo-political risks such as the Russia-Ukraine war, the Middle East conflicts or trade wars and imposition of tariffs could impact the company.

Future Outlook

Centessa expects multiple data readouts across its OX2R agonist pipeline and plans to initiate first-in-human studies of ORX142, with clinical data in acutely sleep-deprived healthy volunteers planned for this year. The company believes this will be another transformative year for Centessa and for the OX2R agonist class overall.

Management Comments

• This was a productive quarter for Centessa, marked by steady progress across our OX2R agonist pipeline, said Saurabh Saha MD PhD, Chief Executive Officer of Centessa.
• We are excited to be at the forefront of developing OX2R agonists starting with ORX750, our most advanced OX2R agonist for the treatment of NT1, NT2 and IH.
• With multiple data readouts expected across our OX2R agonist pipeline, we believe this will be another transformative year for Centessa and for the OX2R agonist class overall, said Dr. Saha.

Industry Context

Centessa is focusing on the orexin pathway, a promising new frontier in neuroscience, to address sleep-wake disorders and other neurological and neuropsychiatric conditions. This puts them in competition with other companies developing therapies in the sleep disorder and neuroscience space.

Comparison to Industry Standards

• It is difficult to compare Centessa directly to industry standards without knowing the specific benchmarks for orexin agonist development.
• However, companies like Jazz Pharmaceuticals, which has Xyrem and Xywav for narcolepsy, and Axsome Therapeutics, which is developing therapies for central nervous system disorders, could be considered comparators in terms of market focus.
• The success of Centessa's ORX750 will depend on its efficacy and safety profile compared to existing treatments and other orexin agonists in development.

Stakeholder Impact

• Shareholders: The progress in the pipeline and strong cash position are positive for shareholders.
• Patients: The development of new therapies for sleep disorders and neurological conditions could benefit patients.
• Employees: The company's progress and financial stability are positive for employees.

Next Steps

• Continue the Phase 2a CRYSTAL-1 study of ORX750 and expect data from all three indications (NT1, NT2, and IH) in 2025.
• Initiate first-in-human studies of ORX142 and share clinical data in acutely sleep-deprived healthy volunteers in 2025, subject to IND clearance.
• Advance ORX489 in IND-enabling studies.

Key Dates

Keywords

ORX750, ORX142, ORX489, Orexin Agonist, Narcolepsy, Idiopathic Hypersomnia, Neurodegenerative Disorders, Neuropsychiatric Disorders, Centessa Pharmaceuticals, Financial Results